Multiple myeloma is a plasma cell malignancy with a heterogeneous genomic profile that remains incurable despite the use of therapies such as alkylating agents, proteasome inhibitors, immunomodulatory drugs, and anti-CD38–targeted mAbs (1, 2). This evidence concerns the gene CD38 and plasma cell myeloma.